Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04940390 · ClinicalTrials.gov registry record · Phase 3
A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Assess STS101 in the Acute Treatment of Migraine
A Phase 3 study, sponsored by Satsuma Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,591
- Enrollment target
NCT04940390: Completed Phase 3 study, sponsored by Satsuma Pharmaceuticals.
NCT04940390 is a Phase 3 study that has completed, run by Satsuma Pharmaceuticals. The registered enrollment target is 1,591 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (106% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04940390, a Phase 3 study, has completed, sponsored by Satsuma Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,591 participants
- Enrollment target
Study Summary
Study STS101-007 is a randomized, double-blind, parallel group, placebo-controlled, multicenter study to evaluate the efficacy, safety, and tolerability of single doses of STS101 (dihydroergotamine nasal powder) in the acute treatment of migraine.
Primary Outcome
The subject's rating was documented on a four-point scale from no pain (= 0), mild pain (= 1), moderate pain (= 2) to severe pain (= 3). Pain freedom means the pain went from moderate (2) or severe (3) to no pain (0).
Interventions
- DRUG Placebo
- DRUG Dihydroergotamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,591 participants |
| Start Date | 2021-06-30 |
| Est. Completion | 2022-10-26 |
| Phase | Phase 3 |
What the finished NCT04940390 record still lists
NCT04940390 is an interventional study that assigns participants to a tested intervention. Its 1,591 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (106% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04940390 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04940390 about?
NCT04940390 is a clinical study titled "A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Assess STS101 in the Acute Treatment of Migraine". Study STS101-007 is a randomized, double-blind, parallel group, placebo-controlled, multicenter study to evaluate the efficacy, safety, and tolerability of single doses of STS101 (dihydroergotamine nasal powder) in the acute treatment of migraine.
What is the current status of trial NCT04940390?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,591 participants. The study started on 2021-06-30. Estimated completion is 2022-10-26.
What interventions are being tested in trial NCT04940390?
The interventions under investigation include: Placebo (DRUG), Dihydroergotamine (DRUG).
Who is sponsoring clinical trial NCT04940390?
This trial is sponsored by Satsuma Pharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04940390's enrollment target sits among peer trials
1,591 147th of 2000 higher than 1,854 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05552222 · 1,590 participants · Phase 3
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- NCT06632457 · 1,590 participants · Phase 3
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
- NCT05243797 · 1,594 participants · Phase 3
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
- NCT00646022 · 1,600 participants
Natural History of Familial Carcinoid Tumor
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI